TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cone Beam vs MDCT for Diagnosis and Pre-operative Evaluation of Otosclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18 years and older)~* Requiring radiological assessment for conductive hearing loss with intact tympanic membrane, confirmed by otoscopy and audiogram~* Signed informed consent~* Affiliated or beneficiary of health insurance~Exclusion Criteria:~* Absence of otosclerosis on the MDCT~* History of middle ear surgery~* Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control~* Patient under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cone Beam CT (Type: EXPERIMENTAL): Each patient will undergo a Cone Beam CT and a MDCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Gestational age \>34 completed weeks (\>=35)~* Age \<48 hours~* A-a DO2 400 to 600, on two post-ductal arterial blood gases one hour apart, while on 100% O2 by oxygen hood~* Post-ductal arterial access~* Admitted to The University of Alabama Birmingham Regional NICU~Exclusion criteria:~* Cardiac disease (structural disease with right to left or mixing lesions), not including patent ductus arteriosus (PDA) or patent foramen ovale (PFO)~* Rapid deterioration requiring mechanical ventilation before entry into the study~* Major malformations~* Major neurologic or metabolic disorder or other illness leading to hypoventilation and hypercarbia

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Hours
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nitric Oxide for Inhalation
- 2 (Type: PLACEBO_COMPARATOR): oxygen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Parents or legally authorized representatives must give signed informed consent before any Registry-related activities are conducted. Assent from the subject should also be obtained where appropriate.~* Patients receiving Increlex® by a qualified practitioner may be enrolled~Exclusion Criteria:

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Increlex patients (Type: None): Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* One or more CNS hemangioblastomas not amendable to surgical resection or recurrent post resection~* Confirmed diagnosis of von-Hippel-Lindau disease~* No prior treatment with VEGF inhibitors~* Index hemangioblastomas lesion at least 5mm on MRI~* No major bleeding event from hemangioblastoma within 90 days~* KPS \> or equal to 60%~* Age \> or equal to 18 years~Exclusion Criteria:~* Prior treatment with VEGF inhibitors~* Major bleeding event from hemangioblastoma within 90 days~* Inability to comply with study and/or follow up procedures~* Life expectancy of less than 12 weeks~* Current or recent (within 4 weeks of the first infusion of this study) participation in an experimental drug study other than a Genentech sponsored bevacizumab cancer study~* Active malignancy will be permissible if treating physician deems that concurrent administration of bevacizumab is not contraindicated and that the patient would be able to complete with the other parameters of the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Refractory or relapsed acute lymphoblastic leukemia~  * Must be in first relapse or have failed to achieve complete remission with 1 prior regimen~* Prior central nervous system (CNS) leukemia allowed provided cerebrospinal fluid is normal~* ECOG Performance status of 0-3~* Bilirubin normal~* Creatinine normal~* Human immunodeficiency virus (HIV) negative~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Hepatitis B positivity~* Bacterial or fungal infection~* Infection requiring treatment with antibiotics~* Active cytomegalovirus infection by molecular detection methods~* Known hypersensitivity to alemtuzumab or its components~* Pregnant or nursing~* Other malignancy within the past 5 years except adequately treated basal cell skin cancer or cervical carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (chemotherapy, enzyme inhibitor therapy) (Type: EXPERIMENTAL): INDUCTION THERAPY: Patients receive methotrexate IV; vincristine IV and asparaginase IM ; oral dexamethasone ; and alemtuzumab SC.~CONSOLIDATION THERAPY: Patients receive methotrexate IV and asparaginase IM.~CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV; leucovorin calcium IV; and oral dexamethasone.~MAINTENANCE THERAPY: Patients receive oral mercaptopurine; oral methotrexate; vincristine IV; and oral dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Implantation in Patients Undergoing CABG

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Patients with ischemic heart disease manifested by Canadian class II or greater angina and/or New York Heart Association class II, III or IV exercise intolerance AND who have undergone diagnostic coronary angiography demonstrating at least 70% diameter narrowing of at least 2 major coronary arteries or branches or at least 50% diameter narrowing of the left main coronary artery.~* Left ventricular systolic dysfunction evaluated by echocardiography or LV angiography (LV ejection fraction less than or equal to 49%).~* No contraindications or exclusions (see below)~* Willingness to participate and ability to provide informed consent~Exclusion Criteria:~* Contraindications to magnetic resonance imaging .~* Need for emergent revascularization.~* Need for concomitant surgical procedure at the time of CABG (e.g. valve repair or replacement, aneurysm resection, etc.).~* Hemodynamically unstable patients.~* Patients with confirmed transmural myocardial infarction within 4 weeks, and/or rising cardiac biomarker proteins (i.e. troponin), and/or worsening ECG changes.~* Prior CABG surgery.~* Stroke within 1 month prior to planned CABG.~* Diagnosed with human immunodeficiency virus (HIV) or any other immune disorder or immunosuppressive medication (e.g. prednisone, cyclophosphamide, etanercept, etc.)~* Organ dysfunction~* Contra-indication for bone marrow aspiration (Thrombocytopenia \< 50.000 mm3, INR \> 2.0, use of antiplatelet agents other than aspirin).~* Hemoglobin less than 8g/dL, white blood cell count less than 4,000/mm3, absolute neutrophil count less than 1500/mm3~* Active infection~* Myelodysplastic syndrome (MDS)~* Significant cognitive impairment~* Any condition associated with a life expectancy of less than 6 months~* Patients known allergic reaction or contraindication to any of the component of the CD133+ enriched cells~* Participation in other studies concomitant with this study~* History of severe ventricular tachy-arrythmias~* Inability or unwillingness to provide written informed consent~* Positive serum pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous CD133+ Bone Marrow Stem Cells (Type: ACTIVE_COMPARATOR): Intra-myocardial injection of autologous CD133+ cells in suspension.
- Carrier Solution (Type: PLACEBO_COMPARATOR): Intra-myocardial inception of carrier solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Soft tissue sarcoma members histologically confirmed~* Tumor primitive complete excision with margins greater than or equal to 10 mm in the soft tissue in all directions during the initial surgery.~A sub-centimeter margin is authorized under an anatomic barrier (fascia, fascia, inter-osseous membrane, periosteum), if surgery is R0 a margin sub-centimeter depth is allowed for superficial tumors if the underlying fascia RESECTED is not invaded.~* Primitive tumors without breaking initial tumor and without tumor residue in the systematic recovery in case of incomplete initial excision margins or doubtful~* WHO less than or equal to 2~* Age greater than or equal to 18 years~* Review extension negative (normal chest CT)~* Information and monitoring possible~* Patient affiliated to social security~Exclusion Criteria:~* Previously treated local sarcoma relapse~* Visceral or lymph node metastases~* pre-operative treatment (chemotherapy or radiotherapy)~* PNET, alveolar rhabdomyosarcoma, Darrier-Ferrand sarcoma~* excision margins of less than 10 mm in one direction or doubtful or unspecified, except under an anatomic barrier (fascia, fascia, inter-osseous membrane, periosteum), if surgery is R0 and tumors if the superficial fascia underlying RESECTED is not invaded.~* Break-tumor during the initial surgery, or residual tumor at second surgery~* Chemotherapy~* Delay between surgery R0 margins greater than or equal to 1 cm (initial surgery or recovery) and the start of radiotherapy exceeding 8 weeks~* History of radiation on the Member~* History of cancer (except carcinoma in situ of the cervix and basal cell skin cancer or in complete remission for over 5 years)~* Pregnant Women~* Patients under guardianship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Absence of Radiotherapy (Type: EXPERIMENTAL): No Radiotherapy; Simple monitoring without active treatment
- Radiotherapy (Type: ACTIVE_COMPARATOR): Radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Palliation of Dyspnea With Mouth Piece Ventilation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* at least moderate dyspnea (NRS = Numeric Rating Scale ≥ 4)~* incurable advanced disease~* able to understand the study and to give informed consent~* would not gain from intensive care or resuscitation according to the treating physician~Exclusion Criteria:~* unable to participate and use MPV due to e.g. delirium or lack of co-operation~* the cause of the dyspnea can be succesfully treated~* unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MPV arm (Type: OTHER): Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Female and male patients ≥ 18 years of age.~2. Patients with schizophrenia based on the Diagnostic of Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).~3. Patients currently treated with oral SGA monotherapy for a minimum of 3 months that are prescribed\* to switch to another oral SGA medication. Patients will be included in a cohort depending on the switching treatment prescribed:~   * Cohort A: patients who are prescribed to switch to lurasidone (lurasidone cohort)~  * Cohort B: patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort) \*Treatment switch and overlap period will be performed according to clinical practice and medical criteria.~4. Written informed consent prior to participation.~Exclusion Criteria:~1. Patients with a known cardiovascular disease or suspected of having a heart disease.~2. Pregnant or breastfeeding women.~3. Patients diagnosed with at least one of the following: depression with psychotic symptoms, schizoaffective disorder, bipolar disorder or organic brain syndromes; Patients with active suicidal ideation or patients who have habitual and sustained consumption of alcohol and / or other toxic substances are also excluded.~4. Patients who had been treated with a long-acting within the last 6 months, or within last year in case of Trevicta®.~5. Concomitant treatments with antipsychotics for insomnia or anxiety (i.e., low doses of quetiapine, etumine, levomepromazine or similar). Concomitant treatment with sedative substances not considered antipsychotics (i.e., benzodiazepines or similar) when they are being taking regularly and at unchanged low doses are allowed.~6. Patients with history of seizures, stroke, neuroleptic malignant syndrome or epilepsy are excluded.~7. Current participation in any clinical trial.~8. Patients for whom further follow-up is not possible at the enrolling site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Patients who are prescribed to switch to lurasidone (lurasidone cohort)
- B (Type: None): Patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject with symptoms of intermittent claudication, such as exercise-induced pain, cramps, fatigue, or other equivalent discomfort, involving large muscle groups of the leg(s) (calf, thigh, buttocks), relieved by rest.~2. Ankle-brachial index ≤ 0.90 acquired according to the American Heart Association guidelines.~3. Highest ankle pressure reduced by at least 25 mm Hg after exercise compared to resting pressure (or loss of previously present Doppler signal for both the posterior tibial and anterior tibial arteries immediately after exercise if arteries were incompressible).~4. Patients on medical treatment for PAD without significant improvement in intermittent claudication within the last 6 months.~Exclusion Criteria:~1. Age \< 18 and \> 80 years.~2. Patients with physician diagnosed chronic kidney disease or heart failure stage II or IV or unstable angina.~3. Echocardiographic evidence of cardiomyopathies and pulmonary hypertension.~4. Patients that have received cancer treatment within the last year (except skin cancer).~5. Severe limitations in mobility due to osteomuscular disorders present at time of interview.~6. Dementia or other mental disorders that prevent patients from following a research protocol present at time of interview~7. Patients engaged in an exercise rehabilitation program within the past 6 months.~8. Patients schedule to undergo an arterial revascularization procedure during the study or have undergone one within the past 6 months.~9. Inconsistent maximal walking distance on the treadmill test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Entresto (Type: ACTIVE_COMPARATOR): oral route
- Placebo group (Type: PLACEBO_COMPARATOR): Oral placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥18 years of age;~2. Patients with histological confirmed melanoma (Stage IIIC or Stage IV, American Joint Commission on Cancer);~3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2;~4. Life expectancy ≥3 months;~5. Treatment with Denileukin Diftitox within 42 days prior to first dose of Ipilimumab;~6. At least 1 site of radiographically measurable disease by immune-related response criteria (irRC);~7. Adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing:~   * Absolute neutrophil count (ANC) ≥1.0 x 109/L;~  * Platelet count ≥100 x 109/L;~  * Hemoglobin ≥8 g/dL;~  * Serum creatinine ≤3 x upper limit of normal (ULN)~  * Total serum bilirubin ≤2 x ULN;~  * Serum aspartate transaminase (AST/SGOT) or serum alanine transaminase (ALT/SGPT) ≤2x ULN, and ≤3 x ULN if liver metastases are present.~8. Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician;~9. Pre-menopausal females and females \<2 years after the onset of menopause should have a negative pregnancy test at Screening. Pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of study drug. Females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year;~10. Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures.~Exclusion Criteria:~1. Prior treatment with Ipilimumab;~2. Known hypersensitivity to Ipilimumab or any of its components;~3. Steroids within one week prior to initiation of Ipilimumab.~4. Pre-existing autoimmune colitis.~5. Patients with an allograft requiring immunosuppression;~6. Known positive human immunodeficiency virus (HIV)~7. Pregnant, breast-feeding, or refusing double barrier contraception, oral contraceptives, or avoidance of pregnancy measures;~8. Have any other uncontrolled infection or medical condition that could interfere with the conduct of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab (Type: EXPERIMENTAL): IV ipilimumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues